|
US20030068322A1
(en)
*
|
1988-04-18 |
2003-04-10 |
Immunomedics, Inc. |
Methods of antibody-directed enzyme-prodrug therapy
|
|
US6228362B1
(en)
|
1992-08-21 |
2001-05-08 |
Immunomedics, Inc. |
Boron neutron capture therapy using pre-targeting methods
|
|
US5846741A
(en)
*
|
1992-08-21 |
1998-12-08 |
Immunomedics, Inc. |
Boron neutron capture therapy using pre-targeting methods
|
|
US6172045B1
(en)
*
|
1994-12-07 |
2001-01-09 |
Neorx Corporation |
Cluster clearing agents
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
DE69833876T2
(de)
*
|
1997-11-10 |
2007-05-24 |
Cytimmune Sciences, Inc. |
Zusammensetzungen und verfahren für die gezielte abgabe von faktoren
|
|
ATE253126T1
(de)
*
|
1998-08-25 |
2003-11-15 |
Univ Washington |
Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen
|
|
US6361774B1
(en)
*
|
1999-09-17 |
2002-03-26 |
Immunomedics, Inc. |
Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
|
|
US6629040B1
(en)
|
1999-03-19 |
2003-09-30 |
University Of Washington |
Isotope distribution encoded tags for protein identification
|
|
AU5727000A
(en)
|
1999-06-07 |
2000-12-28 |
Center For Molecular Medicine And Immunology |
Alpha or beta emitters attached to fragments in radioimmunotherapy
|
|
EP1295123A4
(en)
|
2000-06-12 |
2005-02-02 |
Univ Washington |
SELECTIVE MARKING AND ISOLATION OF PHOSPHOPEPTIDES AND APPLICATIONS TO PROTEOMIC ANALYSIS
|
|
WO2001097855A2
(en)
*
|
2000-06-20 |
2001-12-27 |
Immunomedics, Inc. |
Targeted combination immunotherapy of cancer and infectious diseases
|
|
KR100377946B1
(ko)
*
|
2000-07-15 |
2003-03-29 |
한국과학기술원 |
덴드리머를 이용한 단분자막의 제조방법
|
|
US7445802B2
(en)
*
|
2000-12-26 |
2008-11-04 |
Yeda Research And Development Co. Ltd |
Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
|
|
US6500630B2
(en)
*
|
2001-01-12 |
2002-12-31 |
Mayo Foundation For Medical Education And Research |
Marker for inflammatory conditions
|
|
ATE335515T1
(de)
*
|
2001-03-30 |
2006-09-15 |
Univ Massachusetts |
Morpholinobildgebung und therapie
|
|
CA2447695C
(en)
|
2001-06-01 |
2015-02-24 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
IL159422A0
(en)
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
|
CA2475247C
(en)
*
|
2002-02-07 |
2015-08-04 |
Massachusetts Institute Of Technology |
Anti-pathogen treatments
|
|
US20030157091A1
(en)
*
|
2002-02-14 |
2003-08-21 |
Dyax Corporation |
Multi-functional proteins
|
|
US20040018557A1
(en)
*
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
WO2004062722A2
(en)
*
|
2003-01-08 |
2004-07-29 |
Sloan Kettering Institute For Cancer Research |
Prevention of systemic toxicity during radioimmunotherapy for intravascularly disseminated cancers
|
|
ES2314272T3
(es)
|
2003-01-10 |
2009-03-16 |
Millennium Pharmaceuticals, Inc. |
Metodos para el diagnostico y el tratamiento del cancer.
|
|
US20050059101A1
(en)
*
|
2003-09-10 |
2005-03-17 |
Gordon Ringold |
Bivalent targeting of cell surfaces
|
|
US20050260131A1
(en)
*
|
2004-05-20 |
2005-11-24 |
General Electric Company |
Pharmaceuticals for enhanced delivery to disease targets
|
|
US20060057062A1
(en)
*
|
2004-09-10 |
2006-03-16 |
Trotter Dinko G |
Compositions and methods useful in pretargeted imaging
|
|
EP1716870A1
(en)
*
|
2005-04-29 |
2006-11-02 |
Bracco Imaging S.p.A. |
MRI contrast agents endowed with concentration independent responsiveness
|
|
US20070009427A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Syud Faisal A |
Compounds and methods for enhanced delivery to disease targets
|
|
US20070009435A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Syud Faisal A |
Compositions and methods for enhanced delivery to target sites
|
|
US20070010014A1
(en)
*
|
2005-07-06 |
2007-01-11 |
General Electric Company |
Compositions and methods for enhanced delivery to target sites
|
|
US20070009428A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Syud Faisal A |
Compounds and methods for enhanced delivery to disease targets
|
|
WO2007070680A2
(en)
*
|
2005-12-16 |
2007-06-21 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Optically detectable probes for identification and treatment of tumors
|
|
EP2026650B1
(en)
*
|
2006-06-14 |
2011-03-16 |
Basf Se |
Anti-microbial compositions
|
|
IL182956A0
(en)
*
|
2007-05-03 |
2008-01-20 |
Yeda Res & Dev |
Glycan modified soluble receptors and binding proteins and their use
|
|
JP5429804B2
(ja)
*
|
2007-09-26 |
2014-02-26 |
独立行政法人国立循環器病研究センター |
体内に存在する病因物質の低下剤
|
|
GB0916749D0
(en)
|
2009-09-23 |
2009-11-04 |
Mologic Ltd |
Peptide cleaning agents
|
|
AU2011289579B2
(en)
|
2010-08-10 |
2016-11-17 |
Ecole Polytechnique Federale De Lausanne |
Erythrocyte-binding therapeutics
|
|
US9850296B2
(en)
|
2010-08-10 |
2017-12-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
US9517257B2
(en)
|
2010-08-10 |
2016-12-13 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
JP5992435B2
(ja)
|
2010-12-21 |
2016-09-14 |
コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． |
循環からの生体分子の除去剤
|
|
US20140256639A1
(en)
*
|
2013-02-14 |
2014-09-11 |
The Regents Of The University Of California |
Peptoid neutralizing agents
|
|
CA2946064C
(en)
|
2014-02-21 |
2023-09-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
US10046056B2
(en)
|
2014-02-21 |
2018-08-14 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
US10946079B2
(en)
|
2014-02-21 |
2021-03-16 |
Ecole Polytechnique Federale De Lausanne |
Glycotargeting therapeutics
|
|
US10953101B2
(en)
|
2014-02-21 |
2021-03-23 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
WO2015189477A1
(en)
|
2014-06-13 |
2015-12-17 |
Tenboron Oy |
Conjugates comprising an anti-egfr1 antibody
|
|
EP3638296A1
(en)
|
2017-06-16 |
2020-04-22 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
|
US12485178B2
(en)
|
2018-04-09 |
2025-12-02 |
Yale University |
Bifunctional small molecules to target the selective degradation of circulating proteins
|
|
CA3134765A1
(en)
*
|
2018-04-09 |
2019-10-17 |
Yale University |
Bi-functional molecules to degrade circulating proteins
|
|
US12697391B2
(en)
|
2018-04-09 |
2026-08-04 |
Yale University |
Bi-functional molecules to degrade circulating proteins
|
|
CA3134610A1
(en)
*
|
2018-04-09 |
2019-10-17 |
Yale University |
Bifunctional small molecules to target the selective degradation of circulating proteins
|
|
EP3790577A4
(en)
|
2018-05-09 |
2022-04-27 |
The University of Chicago |
COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
|
|
MX2022009419A
(es)
|
2020-01-31 |
2022-08-25 |
Avilar Therapeutics Inc |
Compuestos de union al asgpr para la degradacion de proteinas extracelulares.
|
|
JP7795810B2
(ja)
|
2020-10-16 |
2026-01-08 |
ザイトックス セラピューティクス アクチボラゲット |
プレターゲットイメージングおよび治療用ｐｎａプローブ
|
|
AU2022268925A1
(en)
|
2021-05-03 |
2023-11-16 |
Avilar Therapeutics, Inc. |
Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
|
|
TW202600606A
(zh)
*
|
2024-02-21 |
2026-01-01 |
美商雅博得樂醫療公司 |
抗體連接子結合物
|
|
TW202611088A
(zh)
|
2024-07-23 |
2026-03-16 |
美商雅博得樂醫療公司 |
5t4結合多肽及其用途
|